Tumor-targeted Delivery of Biologically Active TRAIL Protein

Overview

Journal Cancer Gene Ther

Specialties Genetics
Oncology
Pharmacology

Date 2010 Jan 16

PMID 20075981

Citations 21

Authors

H-Y Zhang

J-h Man

B Liang

T Zhou

C-H Wang

T Li

H-Y Li

W-H Li

B-F Jin

P-J Zhang

J Zhao

X Pan

K He

W-L Gong

X-M Zhang

A-L Li

Affiliations

Soon will be listed here.

Abstract

The tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a potent inducer of tumor cell apoptosis, but concerns of considerable liver toxicity limit its uses in human cancer therapy. Here, we show that i.v. injected Escherichia coli DH5alpha (E. coli DH5alpha) specifically replicates in solid tumors and metastases in live animals. E. coli DH5alpha does not enter tumor cells and suits for being the vector for soluble TRAIL (sTRAIL), which induces apoptosis by activating cell-surface death receptors. With the high 'tumor-targeting' nature, we demonstrate that intratumoral (i.t.) and intravenous injection of sTRAIL-expressing E. coli DH5alpha results in the tumor-targeted release of biologically active molecules, which leads to a dramatic reduction in the tumor growth rate and the prolonged survival of tumor-bearing mice. TRAIL delivery by E. coli DH5alpha did not cause any detectable toxicity to any organs, suggesting that E. coli DH5alpha-delivered sTRAIL protein therapy may provide a feasible and effective form of treatment for solid tumors.

Citing Articles

Multiple mechanisms contribute to acquired TRAIL resistance in multiple myeloma.

Ticona-Perez F, Chen X, Pandiella A, Diaz-Rodriguez E Cancer Cell Int. 2024; 24(1):275.

PMID: 39098932 PMC: 11299348. DOI: 10.1186/s12935-024-03466-3.

Long-Term Tumor-Targeting Effect of as a Drug Delivery System.

Kim G, Lee H, Jeong D, Kim S, So J Pharmaceuticals (Basel). 2024; 17(4).

PMID: 38675383 PMC: 11053500. DOI: 10.3390/ph17040421.

Promising dawn in tumor microenvironment therapy: engineering oral bacteria.

Wang Z, Sun W, Hua R, Wang Y, Li Y, Zhang H Int J Oral Sci. 2024; 16(1):24.

PMID: 38472176 PMC: 10933493. DOI: 10.1038/s41368-024-00282-3.

A global bibliometric and visualized analysis of bacteria-mediated cancer therapy.

Wang J, Maniruzzaman M Drug Discov Today. 2022; 27(10):103297.

PMID: 35654388 PMC: 9530009. DOI: 10.1016/j.drudis.2022.05.023.

Development of a TNF-α-mediated Trojan Horse for bacteria-based cancer therapy.

Hu C, Chang Y, Liu C, Yu Y, Mou K Mol Ther. 2022; 30(7):2522-2536.

PMID: 35440418 PMC: 9263318. DOI: 10.1016/j.ymthe.2022.04.008.

References

Lee C, Wu C, Shiau A . Salmonella choleraesuis as an anticancer agent in a syngeneic model of orthotopic hepatocellular carcinoma. Int J Cancer. 2007; 122(4):930-5. DOI: 10.1002/ijc.23047. View

Zhao M, Yang M, Li X, Jiang P, Baranov E, Li S . Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. Proc Natl Acad Sci U S A. 2005; 102(3):755-60. PMC: 545558. DOI: 10.1073/pnas.0408422102. View

Contag C, Contag P, Mullins J, Spilman S, Stevenson D, Benaron D . Photonic detection of bacterial pathogens in living hosts. Mol Microbiol. 1995; 18(4):593-603. DOI: 10.1111/j.1365-2958.1995.mmi_18040593.x. View

Leverkus M, Neumann M, Mengling T, Rauch C, Brocker E, Krammer P . Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res. 2000; 60(3):553-9. View

Armeanu S, Lauer U, Smirnow I, Schenk M, Weiss T, Gregor M . Adenoviral gene transfer of tumor necrosis factor-related apoptosis-inducing ligand overcomes an impaired response of hepatoma cells but causes severe apoptosis in primary human hepatocytes. Cancer Res. 2003; 63(10):2369-72. View

Nemunaitis J, Cunningham C, Senzer N, Kuhn J, Cramm J, Litz C . Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients. Cancer Gene Ther. 2003; 10(10):737-44. DOI: 10.1038/sj.cgt.7700634. View

Kim S, Kim K, Kwagh J, Dicker D, Herlyn M, Rustgi A . Death induction by recombinant native TRAIL and its prevention by a caspase 9 inhibitor in primary human esophageal epithelial cells. J Biol Chem. 2004; 279(38):40044-52. DOI: 10.1074/jbc.M404541200. View

Kelley S, Harris L, Xie D, Deforge L, Totpal K, BUSSIERE J . Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther. 2001; 299(1):31-8. View

Griffith T, Chin W, Jackson G, Lynch D, Kubin M . Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol. 1998; 161(6):2833-40. View

10.

Nesterov A, Ivashchenko Y, Kraft A . Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) triggers apoptosis in normal prostate epithelial cells. Oncogene. 2002; 21(7):1135-40. DOI: 10.1038/sj.onc.1205151. View

11.

Agrawal N, Bettegowda C, Cheong I, Geschwind J, Drake C, Hipkiss E . Bacteriolytic therapy can generate a potent immune response against experimental tumors. Proc Natl Acad Sci U S A. 2004; 101(42):15172-7. PMC: 523456. DOI: 10.1073/pnas.0406242101. View

12.

THIELE E, ARISON R, BOXER G . ONCOLYSIS BY CLOSTRIDIA. III. EFFECTS OF CLOSTRIDIA AND CHEMOTHERAPEUTIC AGENTS ON RODENT TUMORS. Cancer Res. 1964; 24:222-33. View

13.

MOESE J, MOESE G . ONCOLYSIS BY CLOSTRIDIA. I. ACTIVITY OF CLOSTRIDIUM BUTYRICUM (M-55) AND OTHER NONPATHOGENIC CLOSTRIDIA AGAINST THE EHRLICH CARCINOMA. Cancer Res. 1964; 24:212-6. View

14.

Thamm D, Kurzman I, King I, Li Z, Sznol M, Dubielzig R . Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: phase I evaluation. Clin Cancer Res. 2005; 11(13):4827-34. DOI: 10.1158/1078-0432.CCR-04-2510. View

15.

Zhao M, Yang M, Ma H, Li X, Tan X, Li S . Targeted therapy with a Salmonella typhimurium leucine-arginine auxotroph cures orthotopic human breast tumors in nude mice. Cancer Res. 2006; 66(15):7647-52. DOI: 10.1158/0008-5472.CAN-06-0716. View

16.

GERICKE D, ENGELBART K . ONCOLYSIS BY CLOSTRIDIA. II. EXPERIMENTS ON A TUMOR SPECTRUM WITH A VARIETY OF CLOSTRIDIA IN COMBINATION WITH HEAVY METAL. Cancer Res. 1964; 24:217-21. View

17.

Fox M, Lemmon M, Mauchline M, Davis T, Giaccia A, Minton N . Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered clostridia. Gene Ther. 1996; 3(2):173-8. View

18.

Yoo J, Choi S, Hwang K, Cho W, Jung C, Kwon S . Adeno-associated virus-mediated gene transfer of a secreted form of TRAIL inhibits tumor growth and occurrence in an experimental tumor model. J Gene Med. 2005; 8(2):163-74. DOI: 10.1002/jgm.832. View

19.

Xu Y, Zhu L, Hu B, Fu G, Zhang H, Wang J . A new expression plasmid in Bifidobacterium longum as a delivery system of endostatin for cancer gene therapy. Cancer Gene Ther. 2006; 14(2):151-7. DOI: 10.1038/sj.cgt.7701003. View

20.

Ashkenazi A, Pai R, Fong S, Leung S, Lawrence D, Marsters S . Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest. 1999; 104(2):155-62. PMC: 408479. DOI: 10.1172/JCI6926. View